- Conditions
- Macular Degeneration
- Interventions
- ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321)
- Biological
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 176
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 563
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Linvoseltamab, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Biospecimen Collection
- Biological · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Eosinophilic Gastritis, Eosinophilic Gastroenteritis
- Interventions
- Dupilumab (blinded), Placebo (blinded)
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 12 Years to 70 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 12
- States / cities
- Aurora, Colorado • Chicago, Illinois • Indianapolis, Indiana + 7 more
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease)
- Interventions
- Not listed
- Lead sponsor
- Viz.ai, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Park Ridge, Illinois • Cherry Hill, New Jersey • Philadelphia, Pennsylvania + 2 more
- Conditions
- Thyroid Eye Disease
- Interventions
- Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) alone
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy Volunteers
- Interventions
- REGN2222
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 2
- States / cities
- Daytona Beach, Florida • Evansville, Indiana
- Conditions
- Asthma
- Interventions
- Dupilumab, Placebo
- Drug · Other
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Detroit, Michigan • The Bronx, New York + 2 more
- Conditions
- Uveal Melanoma
- Interventions
- Stereotactic Body Radiation Therapy, Ziv-Aflibercept
- Radiation · Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Carcinoma, Non Small Cell Lung
- Interventions
- Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo, Docetaxel (Taxotere®), Dexamethasone (pre- and post-medication for docetaxel)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 913 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Ovarian Neoplasms
- Interventions
- Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Advanced Non-Small Cell Lung Cancer
- Interventions
- BNT116, Cemiplimab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Santa Monica, California • Louisville, Kentucky + 6 more
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
- Interventions
- REGN5668, Cemiplimab, Ubamatamab, Sarilumab, Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 612 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 13
- States / cities
- Duarte, California • Irvine, California • Orange, California + 8 more
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- REGN910-3, Intravitreal Aflibercept Injection (IAI)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 87
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more
- Conditions
- Cutaneous Squamous Cell Carcinoma
- Interventions
- Cemiplimab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 40
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more
- Conditions
- Dermatitis, Atopic
- Interventions
- Dupilumab, Matching placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 6 Months to 5 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Long Beach, California + 30 more
- Conditions
- Advanced Cutaneous Squamous Cell Carcinoma
- Interventions
- cemiplimab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 432 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Duarte, California • Los Angeles, California + 19 more
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Alirocumab and Cemiplimab
- Combination Product
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Durham, North Carolina
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Dupilumab
- Biological
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- Cemiplimab 350 MG Intravenous Solution, Fianlimab 1600 MG Intravenous Solution
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- ziv-aflibercept
- Biological
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 25 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Eosinophilic Esophagitis, EoE
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Dermatitis Atopic
- Interventions
- Dupilumab SAR231893
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Denver, Colorado
- Conditions
- Postural Orthostatic Tachycardia Syndrome (POTS)
- Interventions
- REGN7544, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 15
- States / cities
- Gilbert, Arizona • Carlsbad, California • Palo Alto, California + 12 more
- Conditions
- Non-Transfusion Dependent Beta-Thalassemia (NTDT)
- Interventions
- REGN7999, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York